Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2021 07:00 ET | Source: Trevena Inc.

Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
September 21, 2020 07:00 ET | Source: Trevena Inc.

Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting

-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting Posters on OLINVYK benefit-risk profile and TRV250 Phase...
December 12, 2019 07:00 ET | Source: Trevena Inc.

Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting

Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a...
November 04, 2019 07:00 ET | Source: Trevena Inc.

Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study

Company expects to resubmit NDA for oliceridine in Q1 2020 Acute migraine proof-of-concept study for TRV250 initiated Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04,...